Delstrigo, an HIV combination that succeeded in registering insurance benefits, is preparing to enter the market in earnest. According to related industries, the HIV combination Delstrigo ( Doravirine 100 mg, Lamivudine 300 mg and Tenofir Disoproxil Fumarate), which is taken once a day by MSD Korea, has now passed the DC of medical institutions such as Sinchon Severance Hospital.

The drug was approved in Korea in January last year, submitted a benefit application at the beginning of this year, and was listed in January.

Delstrigo's benefit indication is "the treatment of HIV-1 infection in adults who have no previous anti-retrovirus treatment experience." Among the ingredients, Doravirin